Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
Noble Gases02:54

Noble Gases

22.8K

The elements in group 18 are noble gases (helium, neon, argon, krypton, xenon, and radon). They earned the name “noble” because they were assumed to be nonreactive since they have filled valence shells. In 1962, Dr. Neil Bartlett at the University of British Columbia proved this assumption to be false.
22.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

948
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
948
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

981
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
981

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same author

Myosin Inhibition in Non-obstructive Hypertrophic Cardiomyopathy: Lessons from ODYSSEY-HCM.

European cardiology·2026
Same author

Lipid-lowering therapy: Evidence and future perspective.

JRSM cardiovascular disease·2026
Same author

[Epigenetic remodeling mechanisms in heart failure and their pathological significance].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same author

Nobiletin Prevents Cardiac Hypertrophy via SIRT5-Mediated Downregulation of p300.

Hypertension (Dallas, Tex. : 1979)·2025
Same author

Immunoglobulin free light chain-κ in association with NT-proBNP levels after smoking cessation.

Future science OA·2025

Related Experiment Video

Updated: Feb 4, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

[Noble Heart Failure Therapy Using Food Compositions].

Tatsuya Morimoto1,2,3, Masafumi Funamoto1,2, Yoichi Sunagawa1,2,3

  • 1Division of Molecular Medicine, School of Pharmaceutical Sciences, University of Shizuoka.

Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan
|October 2, 2018
PubMed
Summary

Curcumin, a natural compound, shows promise in preventing heart failure. Highly absorbable formulations like Theracurmin may improve heart function and patient survival rates.

Keywords:
Theracurminchronic obstructive pulmonary diseasecurcumindiabetes mellitusheart failureliver dysfunction

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.0K

Related Experiment Videos

Last Updated: Feb 4, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.0K

Area of Science:

  • Cardiovascular Research
  • Natural Product Chemistry
  • Pharmacology

Background:

  • Hemodynamic stresses (hypertension, myocardial infarction) activate neurohumoral factors, progressing heart failure.
  • Current treatments (ARBs, ACE inhibitors, β-blockers) target extracellular molecules but have limited long-term efficacy.
  • Novel pharmacological approaches are needed to improve heart failure survival rates.

Purpose of the Study:

  • To review the potential clinical applications of curcumin, a natural polyphenol, for heart failure.
  • To focus on Theracurmin, a novel, highly absorbable curcumin formulation, for cardiovascular diseases.
  • To discuss preliminary data suggesting Theracurmin's benefits for left ventricular diastolic function.

Main Methods:

  • Review of previous studies on curcumin's cardioprotective effects in animal models.
  • Discussion of advancements in curcumin formulation (nanoparticle, micellization) to enhance bioavailability.
  • Summary of ongoing and completed clinical trials investigating Theracurmin for heart failure-related conditions.

Main Results:

  • Curcumin demonstrated efficacy in preventing heart failure in rat models.
  • Highly absorbable curcumin formulations, like Theracurmin, overcome bioavailability challenges.
  • Preliminary data suggest Theracurmin may enhance left ventricular diastolic function.

Conclusions:

  • Curcumin, particularly highly absorbable formulations like Theracurmin, holds significant potential for treating heart failure.
  • Further clinical trials are warranted to establish Theracurmin's efficacy and safety in heart failure patients.
  • Targeting intracellular pathways with novel curcumin formulations could offer a new therapeutic strategy.